Get the Stockscreener App
2.83
2.54%
0.07
After Hours:
2.83
Agenus Inc stock is traded at $2.83, with a volume of 732.00K.
It is up +2.54% in the last 24 hours and up +5.99% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$2.76
Open:
$2.75
24h Volume:
732.00K
Relative Volume:
1.49
Market Cap:
$66.82M
Revenue:
$156.31M
Net Income/Loss:
$-245.76M
P/E Ratio:
-3.3294
EPS:
-0.85
Net Cash Flow:
$-234.16M
1W Performance:
-7.21%
1M Performance:
+5.99%
6M Performance:
-79.15%
1Y Performance:
-81.21%
1-Day Range:
$2.66
$2.91
1-Week Range:
$2.65
$3.045
52-Week Range:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
2.83 | 66.82M | 156.31M | -245.76M | -234.16M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus to Present Groundbreaking Colorectal Cancer Treatment Data at ASCO GI Symposium - StockTitan
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Agenus Inc. Class Action: The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - Kilgore News Herald
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationAGEN - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Victoria Advocate
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus - BioSpace
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) should contact The Gross Law Firm about pending Class Action - Longview News-Journal
HC Wainwright Has Optimistic Outlook of Agenus Q4 Earnings - MarketBeat
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Q1 Earnings Forecast for Agenus Issued By HC Wainwright - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
Walleye Capital LLC Acquires New Holdings in Agenus Inc. (NASDAQ:AGEN) - MarketBeat
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B - BioPharma Dive
Agenus Restructures to Cut Costs 60%, Doubles Down on Promising Cancer Drug Program - StockTitan
Agenus (AGEN) Q3 2024 Earnings Call Transcript - AOL
Agenus (AGEN) Stock Drops 5.50% Amid Biotech Sector Decline - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Short Interest Update - MarketBeat
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
H.C. Wainwright reiterates Neutral on Agenus stock, focus on bot/bal in colorectal cancer - Investing.com India
HC Wainwright Reaffirms "Neutral" Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Agenus secures $22 million mortgage, plans cost cuts By Investing.com - Investing.com Canada
Agenus secures $22 million mortgage, plans cost cuts - Investing.com India
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development - Yahoo Finance
Agenus Secures $22M Mortgage to Advance Cancer Treatment - TipRanks
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Shareholders that lost money on Agenus Inc.(AGEN) should contact - GuruFocus.com
Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
What is B. Riley's Forecast for Agenus FY2024 Earnings? - MarketBeat
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus stock hits 52-week low at $2.56 amid market challenges - Investing.com Australia
Agenus Chooses Flex Databases for Enhanced Pharmacovigilance Solutions - openPR
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
William Blair Weighs in on Agenus' Q4 Earnings (NASDAQ:AGEN) - MarketBeat
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround - Yahoo Finance
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):